CURATIVE BIOTECHNOLOGY INC

We are a life science company seeking to develop, in-license, sub-license or otherwise acquire early mid- or late-stage assets in the therapeutic and medical device areas. We focus on development stage products that can be acquired at advantageous valuations and terms and assets that we believe either already have, or possess the possibility for significant intellectual property. Additionally, we seek to acquire assets that lend themselves to accelerated clinical and/or regulatory development paths. As of the date of this prospectus, we have not submitted any investigational new drug applications (“INDs”) to the FDA for any product candidate.

Current securities

1. S-1/A filingAug 1, 2025
2. S-1 filingMay 6, 2024
3. RW filingFeb 1, 2024
4. S-1/A filingJan 25, 2023
5. D filingJan 18, 2023